Avandia Lawsuit Filed in Dallas Federal Court Against GlaxoSmithKline

A Dallas man died of a heart attack on May 21, 2007, the very same day that an article in the New England Journal of Medicine exposed the heart attack risks related to Avandia, according the the Southeast Texas Record.

Lany Stanford, a type 2 diabetic, took the popular diabetes Avandia drug to help regulate his insulin. According to the Record, Stanford's family doesn't believe it was a coincidence that he died the same day the study was published.

Family members have filed a wrongful death Avandia lawsuit against the maker of Avandia, GlaxoSmithKline.

They allege in the Avandia lawsuit that the pharmaceutical giant "unfairly" convinced the Food and Drug Administration to approve Avandia, and then went on a "marketing assault" with a drug GSK officials knew was harmful.

If you or a loved one has suffered cardiac complications after ingesting Avandia, you deserve the guidance of a knowledgeable drug attorney. Get a free case review by filling out the form below.

Click To Talk To Us Online

Negligence at Issue

Avandia Cases: Wrongful Death Lawsuit Filed in Texas Against Glaxo
Avandia Cases Grow; Wrongful Death Suit Alleges Glaxo was Negligent

Dallas Lawsuit

Avandia Lawsuit Filed in Dallas Federal Court Against GlaxoSmithKline
Dallas Man Dies of Heart Attack the Day News Breaks of Avandia Risks

News & Warnings

Avandia News and Information | Weitz & Luxenberg
Bloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001

Name

Phone

strictly confidential

Your Question

Contact Name
Email Address
Phone Number
When did you start taking Avandia?
Did you experience cardiovascular problems after taking Avandia?
What was the date you experienced cardiac complications?
Did you have any cardiovascular disease before taking Avandia?
Did you suffer a bone fracture after taking either Avandia or Actos?
Please provide detail about your bone fracture injury, including the date of the injury, how the fracture occured and what bone(s) were affected.
Additional information